share_log

力生制药(002393.SZ):药品注射用氢化可的松琥铂酸钠通过仿制药一致性评价

Lisheng Pharmaceuticals (002393.SZ): Hydrocortisone sodium for pharmaceutical injections passed generic drug consistency evaluation

Gelonghui Finance ·  Apr 8 15:45

Gelonghui, April 8, 丨 Li Sheng Pharmaceutical (002393.SZ) announced that recently, Tianjin Lisheng Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” (approval number: 2024B01369, 2024B01370) issued by the State Drug Administration for injectable hydrocortisone sodium (hereinafter referred to as the “drug”) 50mg (according to C21H30O5) and 0.1g (based on C21H30O5).

Indications for injectable hydrocortisone sodium succinate: It is used to rescue critical patients such as toxic infections, anaphylactic shock, severe adrenocortical insufficiency, connective tissue, and severe allergic diseases such as bronchial asthma, and can also be used to prevent and treat acute transplant rejection.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment